Botte L, Bienfait J, Dethier J, Even P, Evrard J L, Fraipont J, Goffin L, Willemse P
Acta Psychiatr Belg. 1981 Nov-Dec;81(6):595-608.
The clinical efficacy and safety of alprazolam was compared to lorazepam in a double blind randomized design involving 82 out-patients suffering from primary anxiety. Seventy four patients (37 on alprazolam and 37 on lorazepam) were evaluable. They were treated with a flexible dose of 0,75 mg to 3 mg of alprazolam per day (average final dose: 1,59 mg) or 3 mg to 12 mg of lorazepam per day (average final dose: 5,97 mg). The results show that the two drugs produce similar efficacious effects at weeks 2 and 4 of the treatment as evaluated using both patient and physician scales. At week 1, as could be expected from an average daily dose of 0,99 mg of alprazolam and of 4,14 mg of lorazepam, efficacy parameters favored lorazepam. Fifty seven side effects were reported in the 37 lorazepam patients while 61 side effects were reported in the 37 alprazolam patients.
在一项双盲随机设计中,将阿普唑仑与劳拉西泮的临床疗效和安全性进行了比较,该设计涉及82名患有原发性焦虑症的门诊患者。74名患者(37名服用阿普唑仑,37名服用劳拉西泮)可进行评估。他们接受了灵活剂量的治疗,阿普唑仑每天0.75毫克至3毫克(平均最终剂量:1.59毫克),或劳拉西泮每天3毫克至12毫克(平均最终剂量:5.97毫克)。结果表明,使用患者和医生量表评估,在治疗的第2周和第4周,两种药物产生相似的疗效。在第1周,从阿普唑仑平均每日剂量0.99毫克和劳拉西泮4.14毫克来看,可以预期疗效参数有利于劳拉西泮。37名服用劳拉西泮的患者报告了57例副作用,而37名服用阿普唑仑的患者报告了61例副作用。